Hydroxyurea lowers total medical costs for pediatric sickle cell anemia

09/3/2013 | DoctorsLounge.com

Despite having higher outpatient costs, hydroxyurea treatment for children with sickle cell anemia had a 21% lower total estimated annual cost than placebo, according to a study in the journal Pediatrics. The hydroxyurea group had fewer hospitalizations compared with the placebo group, but both had similar lengths of stay.

View Full Article in:

DoctorsLounge.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY